Medical management and positive outcome after prolonged recumbency in a case of equine herpesvirus myeloencephalopathy
•A horse severely affected by EHM with long recumbency had a positive outcome.•Urine qPCR tested positive for EHV-1.•EHV-1 DNA in urine appears to persist longer than in nasal and blood samples. A 17-year-old mare presenting with acute fever, weakness and bladder dysfunction was diagnosed with equin...
Gespeichert in:
Veröffentlicht in: | Journal of equine veterinary science 2024-05, Vol.136, p.105063-105063, Article 105063 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •A horse severely affected by EHM with long recumbency had a positive outcome.•Urine qPCR tested positive for EHV-1.•EHV-1 DNA in urine appears to persist longer than in nasal and blood samples.
A 17-year-old mare presenting with acute fever, weakness and bladder dysfunction was diagnosed with equine herpesvirus myeloencephalopathy (EHM). The mare become transiently recumbent, underwent parenteral fluid therapy, plasma infusion, steroidal/nonsteroidal anti-inflammatory drugs (SAID/NSAIDs) and bladder catheterization. After 10 days the mare was hospitalized. Neurological evaluation revealed ataxia and proprioceptive deficits mainly in the hind limbs. The mare was able to stand but unable to rise from recumbency or walk. Secondary complications included Escherichia coli cystitis, corneal ulcers and pressure sores. A full-body support sling was used for 21 days. Medical treatment included systemic antimicrobials, NSAIDs, gradual discontinuation of SAIDs, parenteral fluid therapy and bladder lavage. The mare tested positive for Varicellovirus equidalpha 1 (EHV-1) DNA in nasal swab and blood samples on day 13 and in urine samples on days 13 and 25 after the onset of fever. Neurological signs improved over a period of 34 days and the mare was discharged with mild hind limb weakness/ataxia. Secondary complications resolved within 2 weeks. At the eight-month follow-up, marked improvement in locomotory function had been achieved. |
---|---|
ISSN: | 0737-0806 1542-7412 |
DOI: | 10.1016/j.jevs.2024.105063 |